Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2024
Reporting Period: Second Quarter ended June 30, 2024
Context: This filing announces the issuance of a press release regarding Q2 2024 financial results and schedules a conference call for August 6, 2024.
Key Financial Metrics
The provided text is a cover report referencing a press release (Exhibit 99.1) but does not contain specific financial data tables or values.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. Investors must refer to the referenced press release (Exhibit 99.1) for detailed operational and financial comparisons.
Guidance, Outlook, and Risks
Management Commentary: The Company hosted a conference call on August 6, 2024, to present business and financial results. A webcast is archived on the Company's website for 60 days.
Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in Item 1A ("Risk Factors") of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Legal Disclaimer: Information furnished under Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific Q2 2024 revenue, net income, and cash position figures.
- Access the archived webcast on www.supernus.com for management's detailed commentary on the results.
- Consult the Form 10-K filed on February 27, 2024, for a comprehensive list of risk factors affecting forward-looking statements.
- Verify if any unusual items or contingencies were disclosed in the referenced press release that are not summarized in this 8-K.